Precigen, a biopharmaceutical company specializing in precision medicines, announced its participation in two major investor events: a virtual fireside chat hosted by J.P. Morgan on June 1, and the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10 in Miami Beach. The company's CEO, Helen Sabzevari, and other executives will discuss Precigen's progress and future plans, including its innovative therapies in immuno-oncology, autoimmune disorders, and infectious diseases. These events offer investors insight into Precigen's pipeline and commercial strategy as it advances treatments like PAPZIMEOS for respiratory papillomatosis.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
